Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes

Autor: Carol A. Lange, Andrea R. Daniel, Douglas Yee, Julie H. Ostrander, Antonino B. D'Assoro, Angela L. Gaviglio, Yan Peng, Ganesh V. Raj, Todd P. Knutson, Preethi Ravindranathan
Jazyk: angličtina
Rok vydání: 2014
Předmět:
Cancer Research
Progesterone receptor B
Transcription
Genetic

medicine.drug_class
Progesterone Receptor
Cathepsin D
Estrogen receptor
Breast Neoplasms
Biology
Article
Receptor
IGF Type 1

03 medical and health sciences
Phosphatidylinositol 3-Kinases
0302 clinical medicine
Growth factor receptor
IGF1R
Progesterone receptor
Breast Cancer
Genetics
medicine
Humans
PELP1
Insulin-Like Growth Factor I
Molecular Biology
Estrogen Receptor
030304 developmental biology
Cell Proliferation
0303 health sciences
Estradiol
Estrogen Receptor alpha
DNA
Receptor Cross-Talk
Molecular biology
3. Good health
Protein Structure
Tertiary

Tamoxifen
Estrogen
030220 oncology & carcinogenesis
MCF-7 Cells
Female
Receptors
Progesterone

Estrogen receptor alpha
Co-Repressor Proteins
hormones
hormone substitutes
and hormone antagonists

medicine.drug
Transcription Factors
Zdroj: Oncogene
ISSN: 1476-5594
0950-9232
Popis: Progesterone and estrogen are important drivers of breast cancer proliferation. Herein, we probed estrogen receptor-α (ER) and progesterone receptor (PR) cross-talk in breast cancer models. Stable expression of PR-B in PR-low/ER+ MCF7 cells increased cellular sensitivity to estradiol and insulin-like growth factor 1 (IGF1), as measured in growth assays performed in the absence of exogenous progestin; similar results were obtained in PR-null/ER+ T47D cells stably expressing PR-B. Genome-wide microarray analyses revealed that unliganded PR-B induced robust expression of a subset of estradiol-responsive ER target genes, including cathepsin-D (CTSD). Estradiol-treated MCF7 cells stably expressing PR-B exhibited enhanced ER Ser167 phosphorylation and recruitment of ER, PR and the proline-, glutamate- and leucine-rich protein 1 (PELP1) to an estrogen response element in the CTSD distal promoter; this complex co-immunoprecipitated with IGF1 receptor (IGFR1) in whole-cell lysates. Importantly, ER/PR/PELP1 complexes were also detected in human breast cancer samples. Inhibition of IGF1R or phosphoinositide 3-kinase blocked PR-B-dependent CTSD mRNA upregulation in response to estradiol. Similarly, inhibition of IGF1R or PR significantly reduced ER recruitment to the CTSD promoter. Stable knockdown of endogenous PR or onapristone treatment of multiple unmodified breast cancer cell lines blocked estradiol-mediated CTSD induction, inhibited growth in soft agar and partially restored tamoxifen sensitivity of resistant cells. Further, combination treatment of breast cancer cells with both onapristone and IGF1R tyrosine kinase inhibitor AEW541 was more effective than either agent alone. In summary, unliganded PR-B enhanced proliferative responses to estradiol and IGF1 via scaffolding of ER-α/PELP1/IGF1R-containing complexes. Our data provide a strong rationale for targeting PR in combination with ER and IGF1R in patients with luminal breast cancer.
Databáze: OpenAIRE